Mylan Receives FDA Approval for New Strength -25mg- Metoprolol Tartrate

PITTSBURGH--(BUSINESS WIRE)--Jan. 22, 2004--Mylan Laboratories Inc. (NYSE:MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals' Abbreviated New Drug Application, which provides for a new strength (25 mg) of metoprolol tartrate.

President and COO, Louis J. DeBone stated, "Mylan is the single largest generic supplier of metoprolol tartrate, in 50 mg and 100 mg strengths, in the United States. The addition of a new 25 mg strength further enhances our generic product portfolio and offers a convenient dosage alternative for patients and health care providers."

The new 25 mg product will be available soon.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements", including with regard to the strength of the Company's generic product portfolio and the anticipated commercial acceptance of the 25 mg dosage of metoprolol tartrate. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties regarding market acceptance of and demand for products in the Company's generic portfolio, including the 25 mg strength of metoprolol tartrate; potential product introduction delays, including as a result of the use of legal, regulatory and legislative strategies by the Company's competitors; the Company's dependence on third party suppliers and distributors for the raw materials the Company uses to manufacture its products; the effects of vigorous competition on commercial acceptance of the Company's products and their pricing; the Company's exposure to lawsuits and contingencies associated with its business; the possible negative effects of any interruption of manufacturing at the Company's production facility; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

CONTACT: Mylan Laboratories Inc., Canonsburg
Kris King, 724-514-1800

SOURCE: Mylan Laboratories Inc.